"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India

# AGENDA AT A GLANCE



KAMAL K HALDER ADCI CDSCO (WZ)



OMPRAKASH S. SADHWANI Former Joint Commissioner and controlling Authority Food and Drug Administration (Maharashtra State)



JEAN-DOMINIQUE Subject Matter Expert - PV & Drug Safety Elsevier (France)



DEEPA ARORA Director CLINEXEL Life Sciences



UJWALA NAIK Country Head-Pharmacovigilance Johnson & Johnson



RAHUL GUPTA Vice President, Regulatory Affairs USV



SHIVANI ACHARYA Associate Director – Clinical Development & PV Abbott



INDU NAMBIAR Head Pharmacovigilance Boehringer Ingelheim



ARUN BHATT Consultant – Clinical Research & Development



KARTHIK BABU Multi Country Safety Head-South Asia Sanofi



SRIRUPA DAS Director - Medical Affairs Abbott



MANOJ SWAMINATHAN Chief Manager Head Global Pharmacovigilance Center Piramal



RANJIT BARSHIKAR QbD/CGMP Consulting, Member Editorial Board Journal of Generic Medicines, England

🕊 #VIphv



ROSHAN PALEWAR CEO, Pharma Global Leader DocRoShGlobal Solutions



CHIRAG TELI Head of Medical Services Alkem Laboratories



PAVAN BADALE Head PV Process Excellence Safety case Management Novartis



DHANARAJ E Pharmacovigilance Lead Biocon



CHAITANYA KULKARNI Manager Pharmacovigilance Brillpharma (Subsidiary of Bristol Labs, UK)



UJWALA V. SALVI Founder & Chief Executive Officer Nucleon Therapeutics



PRAVIN GHADGE Head of Clinical Research Services Reliance Life Sciences



PRADEEPA RAMAKRISHNA Global Safety Physician Lead Surveillance Physician AstraZeneca



ANANT PATIL Asst Professor Department of Pharmacology Dr DY Patil Medical College



SOFI JOSEPH Head of Regulatory Affairs and Pharmacovigilance Serdia Pharmaceuticals



VISHWAS SOVANI Founder Director Pharmawisdom

Organized by



Plot No – 07 – 2nd Floor Ekambaram Industrial Estate Alapakkam, Porur Chennai – 600 116

**(**) +91 44 42108101

🌐 info@virtueinsight.com

Key Speakers Include

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India

"Very well organised & very interesting topics selected. Time management & allowing to ask questions were very sufficient as well."

У #VIphv

Head of Clinical Operations - Emerging Markets, Boehringer Ingelheim

# AGENDA AT A GLANCE



KAVYA KADAM Consultant Global Clinical Trials

PRANJAL BORDOLOI Vice President – Clinical, Medical Affairs & PV Veeda Clinical Research



SAKHARAM GARALE Head South-East Asia Operations ACMA & Managing Partner RENOVARE Healthcare Solutions



PRASHANT BODHE Director CliniSearch

# Plus many more COMING SOON .....



## SILVER PARTNER



# EXHBITOR



# SUPPORTED BY



Plot No - 07










Organized by



trial Estate (+91 44 42108101 Porur 0 116

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India



У #VIphv

**Regulatory Inspection Lead, Safety & International** Global Quality, Takeda

# **CONFERENCE INTRODUCTION:-**

Present review described Pharmacovigilance and drug safety in India. Challenges related to Pharmacovigilance programme, roles of physicians/health professionals as well as role of public/patients for successful monitoring are discussed herewith as nowadays, in India a safety of medicines is one of the key parameters along with therapeutic efficacy for success of any drug as ever-increasing range and potency of medicines. A successful Pharmacovigilance programme related to drug safety should be able to answer the key questions. How quickly has the case been identified? As well as what proportion of patient has successfully monitored collectively by doctor, Pharmacist/health professionals. As early detection is the key in reducing adverse events to minimum level or at lateral stage it may be a fatal or challenge to the health professionals. Challenges related to Pharmacovigilance programme in India can be avoided by strictly implementing proper rule and regulation everywhere. Strengthening of public campaigns for drug safety to improve awareness, addition of drug safety study to the curriculum, minimising the level of adverse effects by having sound knowledge about the side effect of the drug as day by day increasing number of medicines may help in monitoring the Pharmacovigilance programme. Interestingly, Improvement of communication regarding Pharmacovigilance between public and health professionals creates awareness so as to minimize adverse occurring. Proper knowledge on Pharmacovigilance would help to health professionals to understand the effectiveness or risk of medicines that they prescribe and ensure a better healthcare to patient.

Virtue Insight's 20th Pharmacovigilance 2019 Conference provides the strongest context, background, updates, new developments, and future direction for regulations and guidance on safety, pharmacovigilance, and risk management strategies that cannot be found in any other meeting. The content of this event is developed by top experts from the biopharmaceutical industry and global regulatory agencies, and Virtue Insight will convene the best speakers from around the world to discuss the current challenges and issues that matter most to professionals working in the field.

We look forward to seeing you personally at our esteemed event.

#### **KEY THEMES DISCUSSED IN THIS CONFERENCE:-**

- Pharmacovigilance and social media: An industry view
- Addressing a number of technical, regulatory and ethical challenges
- Traditional medicines and herbal of pharmacovigilance: Solutions and innovations
- Herbal medicines uses: Developing reliable information on safety
- Discussing on the global pharmacovigilance system for India
- Recent development of pharmacovigilance system in India
- Insure safe use of medicines and minimizing the risks related to the medicinal product
- Data generated during clinical trials to provide information about the common adverse events
- Pharmacovigilance: Guidance of biologics and biosimilars
- Monitoring the safety of biologics and biosimilars
- Pharmacovigilance Analytics: The hype of big data for pharmacovigilance
- Establishing the age of big data in pharmacovigilance
- Real-world example of the development of a successful risk management plan
- How to write a successful risk management plan The current regulatory framework and its global impact
- Implications for the global environment
- Understanding the global regulatory developments and updates
- New regulatory policy, development, and review
- Be part of a major networking opportunity

# AN EVENT TO VOW

Get more from the event, with a broader scope bringing the whole commu-nications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

#### WHY EXHIBIT?

Make Sales Debut new products Profile your brand Meet new business partners Develop key relationships Educate pharma and biotech companies



## WHO WILL YOU MEET

Vice Presidents, Directors, CRO's, Heads and Managers of:

Pharmacovigilance Strategy, Drug Safety/Risk Management, Information and Clinical Data Management, Clinical Research, Research & Development, Product Safety / Assurance Assessment, Patient Safety & Outcomes Research & Data Analysis, Epidemiology project management, Regulatory Affairs and Compliance, Sales & Marketing, Biotech manufacturers

#### From the following:

Pharmaceutical organizations, Generic pharmaceutical companies, Contract research organizations, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants

Organized by



**()** +91 44 42108101 Industrial Estate kkam, Porur nai – 600 <u>116</u>

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India



"Insightful sessions, well structured presentations and speakers sharing highly valuable knowledge and experience. Learned a lot even through the networking breaks."

PhV Manager, Teva Pharmaceutical

# AGENDA AT A GLANCE

# DAY ONE - 7th November 2019

08:30 - Coffee and registration - An opportunity to meet and to network with your conference colleagues.

09:20 / Chairperson opening remarks

RANJIT BARSHIKAR

QbD/CGMP Consulting Member Editorial Board Journal of Generic Medicines, England

## MARKET OVERVIEW & ANALYSIS

09:30 / Pharmacovigilance Perceptions : Protection of Patients

### ARUN BHATT

Consultant - Clinical Research & Development

10:00 'Improving effectiveness and compliance of literature screening – Automation, prioritization and outsourcing'.

#### JEAN-DOMINIQUE

Subject Matter Expert - Pharmacovigilance and Drug Safety Elsevier (France)

10:30 - Morning Coffee/Tea & Discussion

### **CHALLENGES & OPPORTUNITIES**

# 10:50 DISCUSSION WITH EXPERTS: Discussing on the global pharmacovigilance system for India

- Recent development of pharmacovigilance system in India
- · Rising pharmacovigilance issues & business models
- Automating pharmacovigilance processes: Are we already for the upcoming future?
- Improving patient safety and creating crucial awareness to enhance for better clinical practice
- Challenges and process of adverse drug reaction reporting system in India
- How digital transformation and AI can impact pharmacovigilance
- Challenges to implement rules and regulation related to pharmacovigilance program in India and can it be avoided

### Moderator:

## RANJIT BARSHIKAR

**QbD/CGMP Consulting** Member Editorial Board Journal of Generic Medicines, England

### Panellists:

UJWALA NAIK Country Head-Pharmacovigilance Johnson & Johnson ROSHAN PALEWAR CEO, Pharma Global Leader DocRoShGlobal Solutions

SRIRUPA DAS Director - Medical Affairs Abbott

MANOJ SWAMINATHAN Chief Manager Head Global Pharmacovigilance Center Piramal

DHANARAJ E Pharmacovigilance Lead Biocon

# 11:40 DISCUSSION WITH EXPERTS: Ensure safe use of medicines and minimizing the risks related to the medicinal product

- Data generated during clinical trials to provide information about the common adverse events
- Monitor safety during the post-approval period and through out the entire lifecycle of the medicinal product
- Implementing risk management programs by data mining pharmacovigilance safety databases and signal detection
- CDER and FDA: Highlighting the depth and versatility of drug safety initiatives
- Developing drug safety reporting platform that automates complex processes to ensure compliance in the regulatory environment
- Monitoring safety reporting and agreements what needs to be covered? And what happens if it goes wrong?

Moderator:

PRASHANT BODHE Director CliniSearch

Panellists:

OMPRAKASH S. SADHWANI Former Joint Commissioner and controlling Authority Food and Drug Administration (Maharashtra state)

DEEPA ARORA Director CLINEXEL Life Sciences

ARUN BHATT Consultant – Clinical Research & Development

PRADEEPA RAMAKRISHNA

Global Safety Physician Lead Surveillance Physician AstraZeneca

ANANT PATIL Asst Professor Department of Pharmacology Dr DY Patil Medical College

KAVYA KADAM Consultant Global Clinical Trials



Ekambaram Industrial Estate Alapakkam, Porur Chennai – 600 116

-• • • • • • • • • •

+91 44 42108101

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India



"The conference was very well organised and speakers were clear and concise. I enjoyed the panel discussions as it was good to hear different opinions which are based on experiences etc."

Manager – Pharmacovigilance, Kinapse (Syneos Health)

# DAY ONE - 7th November 2019

## 12:30 - Networking luncheon

#### Afternoon Chair Person

#### PRASHANT BODHE Director

CliniSearch

#### 13:50 Pharmacovigilance of biosimilars

DEEPA ARORA

Director **CLINEXEL Life Sciences** 

#### 14:20 **DISCUSSION WITH EXPERTS: Real-world example of** the development of a successful risk management plan

- · Essential risk management plans from an industry point of view
- How to write a successful risk management plan
- Necessary aspects of managing biopharmaceutical product risks and benefits in health care delivery system
- Reporting results of outcomes of activities in the risk management plan
- The regulatory framework for pharmacovigilance in the context of risk management planning
- Stimulating pharma and drug industry for pharmacovigilance practice and software's to use in pharmacovigilance and clinical trials.
- Risk based strategies for safety issues in immuno-oncology
- Updating risk management plan

#### Moderator:

#### PRANJAL BORDOLOI Vice President Clinical Medical Affairs & Pharmacovigilance Veeda Clinical Research

Panellists:

INDU NAMBIAR Head Pharmacovigilance **Boehringer Ingelheim** 

CHIRAG TELI Head of Medical Services Alkem Laboratories

PRAVIN GHADGE Head of Clinical Research Services **Reliance Life Sciences** 

SAKHARAM GARALE Head South-East Asia Operations ACMA & Managing Partner **RENOVARE Healthcare Solutions** 

#### CHAITANYA KULKARNI Manager Pharmacovigilance Brillpharma (Subsidiary of Bristol Labs, UK)

UJWALA V. SALVI Founder & Chief Executive Officer **Nucleon Therapeutics** 

15:10 - Afternoon Tea/Coffee

### REGULATORY

15:30 / The current regulatory framework and its global impact

### SHIVANI ACHARYA

Associate Director - Clinical Development & Pharmacovigilance, Abbott

#### 16:00 **DISCUSSION WITH EXPERTS: Understanding the** global regulatory developments and updates

- New pharmacovigilance guidance in India: Expectation that can significantly change the pharmaceutical safety landscape
- Explaining principles and guidelines for planning and preparing responses to inspection observations
- Plan and conduct a response to inspect observe, including development of a CAPA, measurement, and tracking
- Addressing progression on global harmonization of pragmatic safety requirements
- Regulatory perspective on machine learning in pharmacovigilance
- Challenges in new regulatory policy and development of diagnostic products that combine drugs, devices and biological products
- Emerging pharmacovigilance regulations in emerging markets
- Regulatory trends in clinical safety & pharmacovigilance
- New regulatory policy, development, and review

### Moderator:

### VISHWAS SOVANI Founder Director Pharmawisdom

**Panellists:** 

KAMAL K HALDER ADCI CDSCO (WZ)

**RAHUL GUPTA** Vice President, Regulatory Affairs, USV

SHIVANI ACHARYA Associate Director - Clinical Development & Pharmacovigilance Abbott

**KARTHIK BABU** Multi Country Safety Head-South Asia Sanofi

Organized by



strial Estate nnai – 600 116

+91 44 42108101

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India



"Good opportunity to network with colleagues. Mostly the speakers/panel members were of high calibre and experienced."

Safety Executive Director, Amgen

# AGENDA AT A GLANCE

# DAY ONE - 7th November 2019

# SOFI JOSEPH

Head of Regulatory Affairs and Pharmacovigilance Serdia Pharmaceuticals

#### PAVAN BADALE

Head PV Process Excellence Safety case Management Novartis

16:50 - Chairperson's closing remarks and end of conference





**()** +91 44 42108101

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"


> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India



"A great platform to understand the current practices & situation all across the industry, as well as individual approach of each company toward the goal of patient safety."

Senior Executive, Lupin

AGENDA AT A GLANCE



Organized by



() +91 44 42108101

Plot No - 07

strial Estate

600 116

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 07th November 2019, Kohinoor Continental Hotel, Mumbai, India

"Really top-tier collaboration and experts present at this event. From amazing hosts and chairman to a wonderful venue, this is the PV event that will make an impact on the industry for how we change how we do work."

#VIphv

Head of Clinical Quality, Karyopharm Therapeutics

**REGISTER ONLINE :** 

Link : https://www.bookmytrainings.com/catalogue/event/72619-20th-pharmacovigilance-2019

For Multiple Bookings - Photocopy this form and send it to bookings@virtueinsight.com

### **REGISTRATION FORM**

# **RESERVATION PRICING:**

#### Standard Rate

1 day conference per delegate - Fee: INR 15,000 + GST(18%)

#### For Bulk Booking of More Than 5 Delegates

Please email us at bookings@virtueinsight.com

### **Registration Form Details:**

ForenameSurname
Job Title
Company
GST No (If Applicable)
Official Contact Number
Address
CountryPostcode
PhoneFax

Email .....

I confirm that I have read & agree to the terms and conditions of booking ..... (Please Tick)

### Signature .....

### Methods of Payments:

By Cheque - Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight.

#### By Bank Transfer:

Account Name Account Type	<ul><li>Virtue Insight</li><li>Current</li></ul>
Account Number	- 915020031763553
Bank Name	- Axis Bank
Bank Address	- 2/8 LAMBERT NAGAR, 1st cross street,
	Virugambakkam, Chennai - 600 092
Branch Name	<ul> <li>Virugambakkam, Chennai</li> </ul>
Swift Code	- AXISINBB211
NEFT / IFSC Code	- UTIB0000211
Micro Code	- 600211010

**Oueries:** Should you have any questions on bookings, Please feel free to contact us.

#### Email: info@virtueinsight.com Web: http://www.virtueinsight.com India Office: Tel: +91 44 42108101

#### **General Information Venue:**

Kohinoor Continental Hotel Andheri Kurla Road Andheri (E) Mumbai 400059 - India Tel: 91 22 66919000 / 91 22 28209999

Payment Terms:

Virtue Insight requires the full amount to be paid before the conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full.

#### Substitutions/name changes or cancellations:

There is a 50% liability on all bookings once made, whether by post, fax, or email. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organization and are not transferable between countries.

#### Indemnity:

Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will reschedule the event.

#### Fee:

The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.

#### How we will contact you:

Virtue Insight's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.

#### News Updates:

Please tick if you do not wish to receive email updates in the future



Kohinoor Continental Hotel

Address: Andheri Kurla Road, Andheri (E), Mumbai - 400059, India.

Phone: 91 22 66919000 / 91 22 28209999







+91 44 42108101